Additional contingent milestone payments.

No definition available.

Name:	bxrx_AdditionalContingentMilestonePayments
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate annual base salaries of employment agreements.

+ References

No definition available.

+ Details

Name:	bxrx_AggregateAnnualBaseSalariesOfEmploymentAgreements
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Business acquisition, contingent consideration, equal annual milestone payments.

+ References

No definition available.

+ Details

Name:	bxrx_BusinessAcquisitionContingentConsiderationEqualAnnualMilestonePayments
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business acquisition contingent consideration first milestone payments.

+ References

No definition available.

+ Details

Name:	bxrx_BusinessAcquisitionContingentConsiderationFirstMilestonePayments
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business acquisition, contingent consideration, number of equal annual milestone payments.

+ References

No definition available.

+ Details

Name:	bxrx_BusinessAcquisitionContingentConsiderationNumberOfEqualAnnualMilestonePayments
Namespace Prefix:	bxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Business acquisition contingent consideration possible milestone payments.

+ References

No definition available.

+ Details

Name:	bxrx_BusinessAcquisitionContingentConsiderationPossibleMilestonePayments
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangements maximum milestone payments upon achievement of regulatory and sales milestones.

+ References

No definition available.

+ Details

Name:	bxrx_CollaborativeArrangementsMaximumMilestonePaymentsUponAchievementOfRegulatoryAndSalesMilestones
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative arrangements, milestone payments period.

+ References

No definition available.

+ Details

Name:	bxrx_CollaborativeArrangementsMilestonePaymentsPeriod
Namespace Prefix:	bxrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent milestone payments maximum.

+ References

No definition available.

+ Details

Name:	bxrx_ContingentMilestonePaymentsMaximum
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum regulatory approval and commercialization milestone payments.

+ References

No definition available.

+ Details

Name:	bxrx_MaximumRegulatoryApprovalAndCommercializationMilestonePayments
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum royalty payment percentage.

+ References

No definition available.

+ Details

Name:	bxrx_MaximumRoyaltyPaymentPercentage
Namespace Prefix:	bxrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty payments.

+ References

No definition available.

+ Details

Name:	bxrx_PercentageOfRoyaltyPayments
Namespace Prefix:	bxrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Purchase commitment non cancelable and cancelable.

+ References

No definition available.

+ Details

Name:	bxrx_PurchaseCommitmentNonCancelableAndCancelable
Namespace Prefix:	bxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty payment percentage.

+ References

No definition available.

+ Details

Name:	bxrx_RoyaltyPaymentPercentage
Namespace Prefix:	bxrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SupplyCommitmentLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bxrx_AlkermesPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bxrx_AmendmentToPurchaseAndSaleAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=bxrx_BusinessAcquisitionContingentConsiderationFourthComponentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bxrx_MilestonePaymentsDueBeginningOnFirstAnniversaryOfRegulatoryApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=bxrx_BusinessAcquisitionContingentConsiderationSecondComponentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bxrx_CornellUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bxrx_NeuromuscularBlockingAgentsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=bxrx_RecroPharmaIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bxrx_AlkermesTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bxrx_RegulatoryApprovalAndNetSaleMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=bxrx_BusinessAcquisitionContingentConsiderationFirstComponentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bxrx_MilestonePaymentsDueFollowingRegulatoryApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SupplyCommitmentAxis=bxrx_DexmedetomidineLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SupplyCommitmentAxis=bxrx_FadolmidineLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details) € in Thousands			1 Months Ended	3 Months Ended			6 Months Ended
	Feb. 01, 2021 USD ($) Milestonepayment	Apr. 10, 2015 USD ($)	Feb. 29, 2020 USD ($) Milestonepayment	Mar. 31, 2022 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2017 USD ($)
Supply Commitment [Line Items]
Business acquisition, contingent consideration, equal annual milestone payments				$ 1,000,000
Purchase Commitment
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable							$ 4,621,000
Alkermes Plc \| Amendment to Purchase and Sale Agreement
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones							$ 22,429,000
Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage							30.00%	30.00%
Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments \| Milestonepayment	7
Business acquisition, contingent consideration, equal annual milestone payments	$ 6,400,000
U.S \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones									$ 5,000,000
European \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones									$ 3,000,000
Minimum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage							10.00%	10.00%
Maximum
Supply Commitment [Line Items]
Business acquisition, contingent consideration, equal annual milestone payments				$ 200,000
Maximum \| Executive Officer
Supply Commitment [Line Items]
Aggregate annual base salaries of employment agreement							$ 927,000
Maximum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage							12.00%	12.00%
Recro \| Alkermes Transaction
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 140,000,000
Recro \| Alkermes Transaction \| Regulatory Approval and Net Sales Milestones
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 60,000,000
Collaborative arrangements, milestone payments period		7 years
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, First Component
Supply Commitment [Line Items]
Business acquisition contingent consideration, first milestone payment						$ 5,000,000
Business acquisition contingent consideration possible milestone payments					$ 5,000,000
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage							30.00%	30.00%
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Milestone Payments Due, Following Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments			$ 5,000,000
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments			$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments \| Milestonepayment			7
Business acquisition, contingent consideration, equal annual milestone payments			$ 6,400,000
Recro \| Minimum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage							10.00%	10.00%
Recro \| Maximum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage							12.00%	12.00%
Recro \| Dexmedetomidine License Agreement
Supply Commitment [Line Items]
Contingent milestone payments, maximum							$ 21,420,000	€ 20,500
Amount of royalty payments due or payable							$ 0
Recro \| Dexmedetomidine License Agreement \| Minimum
Supply Commitment [Line Items]
Percentage of royalty payments							10.00%	10.00%
Recro \| Dexmedetomidine License Agreement \| Maximum
Supply Commitment [Line Items]
Percentage of royalty payments							20.00%	20.00%
Recro \| Fadolmidine License Agreement
Supply Commitment [Line Items]
Amount of royalty payments due or payable							$ 0
Additional contingent milestones payment							$ 12,749,000	€ 12,200
Recro \| Fadolmidine License Agreement \| Minimum
Supply Commitment [Line Items]
Percentage of royalty payments							10.00%	10.00%
Recro \| Fadolmidine License Agreement \| Maximum
Supply Commitment [Line Items]
Percentage of royalty payments							15.00%	15.00%